GlassScriptPhysician profile
Madiha Ashraf
NPI 1790936144
$2,276.10
in general payments reported to CMS, 2019-2025
22 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.18 · 2023: $832 · 2024: $844 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.59 | 2023-2025 | Avycaz, Dalvance, Teflaro |
| Viiv Healthcare Company | $276.52 | 2023-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $231.49 | 2023-2025 | |
| Insmed, INC. | $228.29 | 2023-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $170.81 | 2019-2025 | Zerbaxa, Dificid, Delstrigo |
| Shionogi INC | $141.22 | 2023-2024 | Fetroja |
| Novartis Pharmaceuticals Corporation | $116.48 | 2024-2025 | |
| Ucb, INC. | $100.51 | 2024 | Nayzilam, Bimzelx |
| Paratek Pharmaceuticals, INC. | $64.91 | 2023 | Nuzyra |
| Aimmune Therapeutics, INC. | $47.23 | 2023 | |
| Exact Sciences Corporation | $41.48 | 2025 | Cologuard Collection Kit |
| Biogen, INC. | $28.15 | 2025 | Tysabri, Vumerity |
| Boston Scientific Corporation | $27.63 | 2025 | Watchman Flx |
| Theratechnologies INC. | $25.25 | 2023 | Trogarzo, Egrifta |
| Actelion Pharmaceuticals US, INC. | $24.16 | 2024 | Uptravi, Opsumit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $21.53 | 2023 | Vabomere, Orbactiv, Kimyrsa |
| Astellas Pharma US INC | $20.68 | 2023 | Cresemba |
| Neurocrine Biosciences, INC. | $20.33 | 2025 | |
| Nalu Medical, INC. | $19.10 | 2025 | Nalu Neurostimulation System |
| Amgen INC. | $18.90 | 2024 | Prolia, Evenity |
| Janssen Biotech, INC. | $14.83 | 2023 | Symtuza |
| Allergan, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madiha Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.